10-Q: Bausch + Lomb Reports Q1 2025 Results: Revenue Up, But Net Loss Widens Amid Recall

Bausch + Lomb saw a revenue increase in Q1 2025, but a voluntary recall and increased expenses led to a larger net loss compared to the same period last year.

Summary

• Bausch + Lomb's Q1 2025 revenue increased to $1.137 billion from $1.099 billion in Q1 2024.
• The company experienced a net loss of $211 million, compared to a net loss of $163 million in the same quarter of the previous year.
• The Vision Care segment saw revenue increase by 3% to $656 million.
• The Pharmaceuticals segment revenue remained flat at $267 million.
• The Surgical segment revenue increased by 9% to $214 million.
• The company announced a voluntary recall of certain enVista IOL products, leading to an inventory reserve charge of $15 million.
• Selling, general, and administrative expenses increased by 12% to $563 million.
• Research and development expenses increased by 5% to $86 million.
• The company's cash and cash equivalents and restricted cash decreased to $215 million from $325 million at the beginning of the period.
• The company expects to make interest payments of approximately $320 million and mandatory debt amortization payments of $30 million for the period April 1, 2025 through December 31, 2025 under its Senior Secured Credit Facilities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, the net loss widened due to the recall and increased expenses. The company is taking steps to address the issues, but the near-term outlook is uncertain.

Positives

• Overall revenue increased by 3% compared to the same period last year.
• The Surgical segment showed strong revenue growth of 9%.
• The Vision Care segment saw revenue increase by 3% to $656 million.
• The company has returned to full production of all enVista IOLs.
• Lumify Preservative Free, for which the New Drug Application (NDA) was approved by the U.S. Food and Drug Administration (the FDA) in April 2024, began launching in the first quarter of 2025.

Negatives

• Net loss increased to $211 million, compared to $163 million in the same quarter last year.
• The voluntary recall of enVista IOL products led to a $15 million inventory reserve charge.
• Selling, general, and administrative expenses increased by 12%.
• Pharmaceuticals segment profit decreased by $42 million.
• Cash and cash equivalents decreased by $110 million.

Risks

• The voluntary recall of enVista IOL products could impact future sales and market share.
• Ongoing macroeconomic conditions and potential recessionary pressures could adversely affect revenues and margins.
• The company faces risks associated with the ongoing conflicts between Russia and Ukraine and in the Middle East.
• The company's indebtedness could affect its ability to meet its obligations.
• The company faces risks associated with generic competition and loss of exclusivity for certain products.

Future Outlook

The company is focused on advancing its pipeline, identifying new product opportunities, and managing the impact of macroeconomic factors and the enVista IOL recall. The company expects to return to full market supply in the U.S. in the following weeks.

Industry Context

The report reflects the challenges and opportunities in the global eye health market, including competition, regulatory oversight, and the impact of macroeconomic factors. The company's performance is influenced by trends such as the aging population, increasing prevalence of eye diseases, and technological advancements in eye care products and services.

Comparison to Industry Standards

• It is difficult to compare Bausch + Lomb's results directly to industry standards without specific competitor data.
• However, companies like Alcon, Johnson & Johnson Vision, and Novartis (in its ophthalmology division) are key competitors.
• Alcon, for example, also operates in surgical and vision care, and comparing growth rates in these segments would provide a benchmark.
• The 3% revenue growth is moderate; industry leaders often aim for higher growth, but this is impacted by the recall.
• The increased net loss is concerning and needs to be compared to peers to assess if it's an isolated issue or industry-wide.
• The SG&A increase should be benchmarked against competitors to see if Bausch + Lomb is spending efficiently.

Legal Proceedings

• Bausch + Lomb is involved in various legal and administrative proceedings, including product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues.
• The company is a defendant in multidistrict antitrust litigation (MDL) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation.
• The company is named in a number of product liability lawsuits involving the Shower to Shower body powder product.
• The company is involved in intellectual property matters, including patent litigation related to PreserVision and Lumify products.

Related Party Transactions

• Certain transactions between Bausch + Lomb and BHC and affiliate businesses are cash-settled on a current basis.
• The company has entered into a Master Separation Agreement (MSA) and other agreements with BHC that govern the relationship between BHC and the Company following the completion of the B+L IPO.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the impact of the enVista IOL recall.
• Employees may be affected by potential restructuring and cost savings programs.
• Customers may experience disruptions in the supply of enVista IOL products.
• Suppliers may be affected by changes in manufacturing and sourcing strategies.

Next Steps

• The company will focus on returning to full market supply of enVista IOL products in the U.S.
• The company will continue to advance its product pipeline and identify new product opportunities.
• The company will monitor and manage the impact of macroeconomic factors and geopolitical events.

Key Dates

Keywords

Bausch + Lomb, Financial Results, Q1 2025, Revenue, Net Loss, enVista IOL Recall, Pharmaceuticals, Vision Care, Surgical, Financial Performance